Xeris Pharmaceuticals Inc (XERS)

Currency in USD
6.600
+1.110(+20.22%)
Closed·
After Hours
6.6000.000(0.00%)
·

Xeris Pharmaceuticals (XERS) Stock Forecast & Price Target

Advanced Equity Forecast
Overall Consensus
Strong Buy
4 Buy
1 Hold
0 Sell
Data based on a poll of the past 3 months

Analysts 12-Month Price Target

Average 6.300
(-4.55% Downside)

Past 24 Months

12-Month Forecast

Analyst Ratings

Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy7.00+6.06%6.00MaintainJun 05, 2025
Oppenheimer
Buy7.00+6.06%6.00MaintainMay 09, 2025
Oppenheimer
Buy6.00-9.09%5.00MaintainMar 07, 2025
Craig-Hallum
Buy6.50-1.52%5.00MaintainMar 07, 2025
Piper Sandler
Hold4.00-39.39%3.00MaintainMar 07, 2025

Fair Value

Average
Downside
Uncertainty
Spread
Market Range
52 weeks
$2
$7
Analyst Targets
5 analysts
$4
$7
Fair Value
11 models

FAQ

What Is the Price Target for Xeris Pharmaceuticals (XERS) According to Analysts?

According to projections from 5 analysts, the average 12-month price target for Xeris Pharmaceuticals is 6.3, with a high estimate of 7 and a low estimate of 4.

What Is XERS’s Potential Upside or Downside, Based on the Analysts’ Average Price Target?

Xeris Pharmaceuticals has a potential Downside of -4.55%, based on analysts’ average price target.

How Has Xeris Pharmaceuticals Stock Performed Over the Past 52 Weeks?

The Xeris Pharmaceuticals 52-week range spans from 2.18 to 7.09.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.